Protea Fund - Sectoral Biotech Opportunities Fund PF EUR/  LU1176838347  /

This Sub-Fund invests primarily in innovative biotech companies developing novel drugs in therapeutic areas with large unmet medical needs. Investments are made across all market caps, with significant exposure to mid- and small-cap biotech companies, due to their high degree of innovation. Novel and differentiated treatments benefit from a favorable regulatory and commercial environment, with the potential for shortened development timelines, rapid market adoption as well as strong pricing and operating margins. Innovation in biotech has created large new markets, and tremendous commercial potential remains in many diseases and novel therapeutic modalities, such as mRNA and gene therapy. While respecting the principle of risk diversification, the Sub-Fund's net assets are primarily invested in equities and equity-related securities (such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs), European Depositary Receipts (EDRs)) issued by innovative small, mid and large cap biotech companies which are active in the human medicine sector. While no geographical restrictions apply, the Sub-Fund's investments are centered in North America and Western Europe. The Sub-Fund may invest in transferable securities and money market instruments from new issues to benefit from particularly innovative projects in the healthcare sector, in particular in innovative projects in the drugs sector. Up to 10% of the Sub Fund's net assets may be invested in Special Purpose Acquisition Companies. The Sub-Fund may invest up to 33% of its net assets, via Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect, in China A-Shares. Up to 33% of the Sub-Fund's net assets may be invested outside the aforementioned investment universe including, but not limited to equities of issuers of other business segments than biotech, in fixed and variable interest securities. The Sub-Fund may not invest more than 10% of its net assets in other UCIs or UCITS.

This Sub-Fund invests primarily in innovative biotech companies developing novel drugs in therapeutic areas with large unmet medical needs. Investments are made across all market caps, with significant exposure to mid- and small-cap biotech companies, due to their high degree of innovation. Novel and differentiated treatments benefit from a favorable regulatory and commercial environment, with the potential for shortened development timelines, rapid market adoption as well as strong pricing and operating margins. Innovation in biotech has created large new markets, and tremendous commercial potential remains in many diseases and novel therapeutic modalities, such as mRNA and gene therapy.